Skip to main content

Kyprolis

Generic name: carfilzomibkar-FILZ-oh-mib ]
Dosage form: Infusion
Drug class: Proteasome inhibitors

Medically reviewed by Melisa Puckey, BPharm. Last updated on Oct 9, 2023.

What is Kyprolis?

Kyprolis (carfilzomib) is a cancer medicine used to treat types of multiple myeloma when other medicines have not worked or have stopped working. Kyprolis is from a class of medicines called proteasome inhibitors that slow the spread of cancer and cause cancer cells to die. Multiple myeloma is a cancer of plasma cells (a type of white blood cell).

Kyprolis works by blocking proteasome, which normally breaks down damaged or unneeded proteins within cells. This means that more abnormal proteins build up in the cancer cells, which causes the cancer cells to die.

Kyprolis became an FDA-approved medicine on July 20, 2012.

Who can use Kyprolis?

Kyprolis is an FDA-approved medicine indicated to treat relapsed or refractory multiple myeloma in adults who have received one to three lines of therapy in combination with:

Kyprolis is also FDA-approved as a single treatment agent in adults with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Kyprolis side effects

Common Kyprolis side effects may include:

Serious Kyprolis side effects

Get emergency medical help if you have signs of an allergic reaction to Kyprolis: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur within 24 hours after the injection. Tell your caregiver right away if you feel weak, nauseated, chilled or feverish, light-headed, or if you have joint or muscle pain, a cold sweat, chest pain or tightness, trouble breathing, or swelling in your face.

Kyprolis may cause a serious brain infection that can lead to disability or death. Call your doctor right away if you have problems with speech, thought, vision, or muscle movement. These symptoms may start gradually and get worse quickly.

Also, call your doctor at once if you have:

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

Kyprolis can affect your heart or lungs. Call your doctor at once if you have chest pain, pounding heartbeats, shortness of breath (even with mild exertion or while lying down), swelling of your hands or feet, feeling like you might pass out, wheezing, gasping for breath, cough with foamy mucus, or blue-colored appearance of your lips and skin.

Before taking this medicine

To make sure Kyprolis is safe for you, tell your doctor if you have ever had:

Consider antiviral prophylaxis to decrease the risk of shingles reactivation (herpes zoster).

Pregnancy

You should not use Kyprolis if you are pregnant or planning to become pregnant,  or if you plan to father a child. if you are a female of reproductive potential you may be required to do a pregnancy test before starting Kyprolis treatment.

Kyprolis can harm an unborn baby if the mother or the father is using this medicine.

Breastfeeding

Do not breastfeed while using this medicine, and for at least 2 weeks after your last dose.

How will I receive Kyprolis?

Kyprolis is given as an infusion into a vein which will take 10 minutes to 30 minutes, depending on your treatment protocol. A healthcare provider will give you this injection.

Your treatment may be once or twice a week.

You may be given other medications to help prevent serious side effects or infections. Keep using these medicines for as long as your doctor has prescribed.

You will need frequent medical tests, and your next dose may be delayed based on the results.

Call your doctor if you have ongoing vomiting or diarrhea, or if you are sweating more than usual. You can easily become dehydrated while receiving this medication. Avoid dehydration by drinking plenty of liquids before and after your injections.

Dosing Information

Your healthcare provider will work out the correct dose and regime for your treatment.

Kyprolis once weekly20/70 mg/m2 (30-minute infusion) is administered in combination with:

Kyprolis twice weekly  20/56 mg/m2 (30-minute infusion) is administered as monotherapy or in combination with:

Kyprolis twice Weekly 20/27 mg/m2 (10-minute infusion) is administered as monotherapy or in combination with

For more detailed information on Kyprolis dosing click the link below.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your Kyprolis injection.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while receiving Kyprolis?

Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired.

Storage

Ingredients

Active ingredient: carfilzomib

Inactive ingredients: betadex sulfobutyl ether sodium, anhydrous citric acid, sodium hydroxide, water.

Company

Amgen Kyprolis

Manufactured for:
Onyx Pharmaceuticals, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 U.S.A.

Popular FAQ

Kyprolis (carfilzomib) is a type of chemotherapy drug. It works by inhibiting proteasomes - a complex of proteases (enzymes), which break down proteins in the body. Continue reading

More FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.